Results 181 to 190 of about 1,651 (200)
Some of the next articles are maybe not open access.
Astatine-211: Its possible applications in cancer therapy
International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1986The cyclotron-produced radiohalogen, 211At, is eminently suitable as a possible therapeutic radionuclide. It decays by the emission of 6.8 MeV mean energy alpha-particles, which from a radiobiological viewpoint are of near optimal therapeutic LET.
openaire +2 more sources
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213
European Journal of Nuclear Medicine and Molecular Imaging, 2008Radioimmunotherapy (RIT) with β-emitting radionuclides is an established part of the treatment of some haematological malignancies. Over the past two decades, new αemitters with a short half-life have also emerged and started to be considered for use in RIT [1], as Cherel and colleagues, of the Department of Cancerology, University of Nantes, INSERM ...
openaire +2 more sources
Astatine-211 imaging by a Compton camera for targeted radiotherapy
Applied Radiation and Isotopes, 2018Astatine-211 is a promising radionuclide for targeted radiotherapy. It is required to image the distribution of targeted radiotherapeutic agents in a patient's body for optimization of treatment strategies. We proposed to image 211At with high-energy photons to overcome some problems in conventional planar or single-photon emission computed tomography ...
Yuto Nagao +5 more
openaire +2 more sources
Measuring astatine-211 distributions with SPECT.
Physics in medicine and biology, 1993We have investigated standard SPECT techniques (rotating gamma cameras, multi-hole collimators, and filtered backprojection reconstruction) for imaging astatine-211 distributions. Since 211At emits alpha particles, this nuclide has potential for use in radiotherapy.
T G, Turkington +5 more
openaire +1 more source
Microdosimetry of Astatine-211 Using Histological Images: Application to Bone Marrow
Radiation Research, 1997A method is presented for calculating the small-scale dosimetry of 211At in red bone marrow using chord-length distributions obtained from digitized histological images. This study used histological samples of bone marrow from beagle dogs to convey morphological information about cell conglomerations within bone marrow. Two 211At activity distributions
G, Akabani, M R, Zalutsky
openaire +2 more sources
Astatine-211 labelled proteins and their stability in vivo
Journal of Radioanalytical and Nuclear Chemistry Articles, 1989An organic compound labelled by using radioastatine was conjugated to a protein.211At reacts with the diazo-compound of para-aminobenzoic acid to yield para-astatobenzoic acid, which is separated by ether extraction and high performance liquid chromatography (HPLC) and then conjugated with IgG and bovine serum albumin (BSA) via an acylation reaction ...
Yi Changhou +5 more
openaire +1 more source
A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy
International Journal of Radiation Oncology*Biology*Physics, 1987Astatine-211 is an alpha-emitter with a short half-life (7.2 hr). This paper discusses the potential of 211At targeted by antibodies for tumor therapy and the possible advantage of 211At over beta- and gamma-emitting radionuclides such as 131I currently employed in the field of radioimmunotherapy.
openaire +2 more sources
Influence of radiolysis on astatine-211 chemistry
Nuclear Medicine and Biology, 2022Mohammad Ghalei +7 more
openaire +1 more source
Astatine-211: The Chemistry Infrastructure
Journal of Medical Imaging and Radiation Sciences, 2019Sture Lindegren +5 more
openaire +1 more source
Separation of astatine-211 from bismuth metal
Analytica Chimica Acta, 1973R D, Neirinckx, J A, Smit
openaire +2 more sources